TY - JOUR
T1 - Modulation of chemosensitivity by alpha interferon in multiple myeloma and non-Hodgkin's lymphoma
AU - Iaffaioli, Rosario V.
AU - Facchini, Gaetano
AU - Tortoriello, Anna
AU - Scala, Stefania
AU - Pacelli, Roberto
AU - La Mura, Giuseppe
AU - Pagliarulo, Clorindo
AU - Palmieri, Giovanella
AU - Caponigro, Francesco
PY - 1996/7
Y1 - 1996/7
N2 - Low-grade non-Hodgkin's lymphoma and multiple myeloma are chemosensitive malignancies, but are rarely curable because of primary or acquired drug resistance. Interferon has been shown to modulate the multidrug resistance phenotype and to reinduce chemosensitivity in patients with chemoresistant tumors. Fifteen patients with multiple myeloma and 64 patients with low/intermediate grade non-Hodgkin's lymphoma unresponsive to initial chemotherapy were treated with alpha 2b interferon for 2 months. In case of an objective response, treatment was continued until disease progression; non-responding patients received the same chemotherapy to which they were resistant, preceded by a 5 day course of interferon. Interferon salvage monotherapy induced an objective response in 1/15 patients with multiple myeloma and in 7/64 patients with non-Hodgkin's lymphoma. An objective response was achieved after retreatment with first-line chemotherapy preceded by interferon in 4/14 patients (28.6%) with multiple myeloma and in 20/56 evaluable patients (35.7%) with non-Hodgkin's lymphoma. Toxicity was moderate, predictable, manageable, and never caused interruption of the treatment. Interferon appears to be able to modulate chemosensitivity of tumors refractory to chemotherapy with several potential mechanisms, including an effect on drug accumulation; its utilization in this setting warrants further evaluation.
AB - Low-grade non-Hodgkin's lymphoma and multiple myeloma are chemosensitive malignancies, but are rarely curable because of primary or acquired drug resistance. Interferon has been shown to modulate the multidrug resistance phenotype and to reinduce chemosensitivity in patients with chemoresistant tumors. Fifteen patients with multiple myeloma and 64 patients with low/intermediate grade non-Hodgkin's lymphoma unresponsive to initial chemotherapy were treated with alpha 2b interferon for 2 months. In case of an objective response, treatment was continued until disease progression; non-responding patients received the same chemotherapy to which they were resistant, preceded by a 5 day course of interferon. Interferon salvage monotherapy induced an objective response in 1/15 patients with multiple myeloma and in 7/64 patients with non-Hodgkin's lymphoma. An objective response was achieved after retreatment with first-line chemotherapy preceded by interferon in 4/14 patients (28.6%) with multiple myeloma and in 20/56 evaluable patients (35.7%) with non-Hodgkin's lymphoma. Toxicity was moderate, predictable, manageable, and never caused interruption of the treatment. Interferon appears to be able to modulate chemosensitivity of tumors refractory to chemotherapy with several potential mechanisms, including an effect on drug accumulation; its utilization in this setting warrants further evaluation.
KW - Alpha interferon
KW - Drug resistance
KW - Multiple myeloma
KW - Non-Hodgkin's lymphoma
UR - http://www.scopus.com/inward/record.url?scp=0030177326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030177326&partnerID=8YFLogxK
M3 - Article
C2 - 9414408
AN - SCOPUS:0030177326
VL - 1
SP - 226
EP - 230
JO - Journal of Experimental Therapeutics and Oncology
JF - Journal of Experimental Therapeutics and Oncology
SN - 1359-4117
IS - 4
ER -